Walleye Capital’s Q32 Bio QTTB Stock Holding History

Walleye Capital’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,218	Closed	-$80K	–	2642
2021 Q4	$80K	Buy	+1,218	New	+$118K	﹤0.01%	1725

Other funds holding QTTB

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Walleye Capital's QTTB Position: Q1 2022 in Review

Walleye Capital sold out of Q32 Bio (QTTB) in Q1 2022, closing a stake of 1,218 shares — an estimated $80K sold.

Walleye Capital first reported a position in QTTB in Q4 2021 and held it in 1 quarter. The position peaked at $80K in Q4 2021. 106 funds tracked by Wall St. Rank hold QTTB as of Q1 2022.

Walleye Capital reported no remaining Q32 Bio position as of Q1 2022 after selling out during the quarter.
Walleye Capital sold 1,218 Q32 Bio shares in Q1 2022, an estimated $80K.
Walleye Capital first reported a position in Q32 Bio in Q4 2021 and held it in 1 quarter.
Walleye Capital's Q32 Bio position peaked at $80K in Q4 2021.
106 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.